Voltaren and Amyloidosis - a phase IV clinical study of FDA data

Summary:

Amyloidosis is reported as a side effect among people who take Voltaren (diclofenac sodium), especially for people who are female, 60+ old, also take Prednisolone, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Amyloidosis when taking Voltaren. It is created by eHealthMe based on reports of 81,356 people who have side effects when taking Voltaren from the FDA, and is updated regularly.

What is Voltaren?

Voltaren has active ingredients of diclofenac sodium. It is often used in arthritis. eHealthMe is studying from 82,346 Voltaren users. Check the latest studies of Voltaren.

What is Amyloidosis?

Amyloidosis (a tumour within which amyloid is produced) is found to be associated with 242 drugs and 366 conditions by eHealthMe. Check the latest studies of Amyloidosis.

On Jul, 12, 2026

81,356 people reported to have side effects when taking Voltaren.
Among them, 14 people (0.02%) have Amyloidosis.

Among these 14 people:

What is the gender of people who have Amyloidosis when taking Voltaren? *

female: 71.43 %
male: 28.57 %

What is the age of people who have Amyloidosis when taking Voltaren? *

What are other drugs people take besides Voltaren? *

What are other side effects people have besides Amyloidosis? *

C-Reactive Protein Increased: 4 people, 28.57%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 3 people, 21.43%
Abdominal Pain: 3 people, 21.43%
Acute Kidney Failure: 3 people, 21.43%
Septic Shock (shock due to blood infection): 3 people, 21.43%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 21.43%
Organising Pneumonia (pathologically by the presence in the distal air spaces of buds of granulation tissue): 3 people, 21.43%
Haematocrit Decreased: 2 people, 14.29%
Hypoproteinaemia (too little prolactin circulating in the blood): 2 people, 14.29%
Cytomegalovirus Infection: 2 people, 14.29%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 64.29%
Osteoporosis (bones weak and more likely to break): 4 people, 28.57%
Gastritis (inflammation of stomach): 4 people, 28.57%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 21.43%
Diabetes: 3 people, 21.43%
Weight Increased: 1 person, 7.14%
Reflux Oesophagitis (an oesophageal mucosal injury that occurs of gastric contents into the oesophagus): 1 person, 7.14%
Peripheral Swelling: 1 person, 7.14%
Peripheral Occlusive Disease (narrowing of blood vessels that restricts blood flow): 1 person, 7.14%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Voltaren and have Amyloidosis?

- Check whether Amyloidosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Voltaren:

Voltaren (82,346 reports)

Amyloidosis treatments and more:

Amyloidosis (9,651 reports)

Browse all side effects of Voltaren:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Amyloidosis:

Amyloidosis (242 drugs)

Browse all the conditions that are associated with Amyloidosis:

Amyloidosis (366 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on diclofenac sodium (the active ingredients of Voltaren) and Voltaren (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.